Statement by the Administrator on DEA’s Settlement Agreement with Truepill Pharmacy
DEA is steadfastly committed to ensuring that all Americans get access to needed medications, while also ensuring patient safety. Stimulants are important medications for both children and adults. They are also Schedule II controlled substances that can be highly addictive and that require the greatest care in prescribing. When inappropriately prescribed, stimulants can lead to addiction and overdose. DEA is committed to preventing the wrongful prescribing of these medications and to holding accountable everyone in the prescription drug supply chain—including doctors, pharmacies, and corporate platforms—that endanger patient safety. With this settlement, Truepill has accepted responsibility for operating an unregistered online pharmacy, filling prescriptions for Schedule II controlled substances in excess of the 90-day limit, and filling prescriptions written by medical providers who did not have the required licenses, all in violation of federal law. As a consequence, Truepill has agreed to revise its policies and procedures, train its pharmacists on implementing new controls and identifying improper prescriptions, and submit to heightened compliance measures for a period of four years.
For more information, DEA previously issued a press release on the Order to Show Cause on Truepill on December 15, 2022.
# # #